These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 2545062

  • 1. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin).
    Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA.
    Acta Endocrinol (Copenh); 1989 Jul; 121(1):34-40. PubMed ID: 2545062
    [Abstract] [Full Text] [Related]

  • 2. Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones.
    Osei K, O'Dorisio TM.
    Ann Intern Med; 1985 Aug; 103(2):223-5. PubMed ID: 2861769
    [No Abstract] [Full Text] [Related]

  • 3. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon.
    Gama R, Marks V, Wright J, Teale JD.
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):117-20; discussion 120-2. PubMed ID: 7641403
    [Abstract] [Full Text] [Related]

  • 4. Chronic treatment of a benign insulinoma using the long-acting somatostatin analogue SMS 201-995.
    Glaser B, Rösler A, Halperin Y.
    Isr J Med Sci; 1990 Jan; 26(1):16-9. PubMed ID: 2155884
    [Abstract] [Full Text] [Related]

  • 5. Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?
    Stehouwer CD, Lems WF, Fischer HR, Hackeng WH.
    Neth J Med; 1989 Aug; 35(1-2):86-94. PubMed ID: 2550827
    [Abstract] [Full Text] [Related]

  • 6. Remission of symptoms of chemotherapy-refractory metastatic insulinoma using octreotide.
    Longnecker SM.
    Drug Intell Clin Pharm; 1988 Feb; 22(2):136-8. PubMed ID: 2894965
    [Abstract] [Full Text] [Related]

  • 7. A case of malignant insulinoma: successful control of glycemic fluctuation by replacing octreotide injections with octreotide LAR injections.
    Okamoto M, Kishimoto M, Takahashi Y, Osame K, Noto H, Yamamoto-Honda R, Kajio H, Tokuhara M, Edamoto Y, Endo H, Igari T, Kubota K, Noda M.
    Endocr J; 2013 Feb; 60(8):951-7. PubMed ID: 23665775
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the long-acting somatostatin analogue octreotide in the management of insulinoma in three dogs.
    Simpson KW, Stepien RL, Elwood CM, Boswood A, Vaillant CR.
    J Small Anim Pract; 1995 Apr; 36(4):161-5. PubMed ID: 7603057
    [Abstract] [Full Text] [Related]

  • 9. [Benign insulinoma. Efficacy of preoperative treatment for persistent hyperinsulinemia using a synthetic somatostatin analog].
    Esposito V, Esposito D, Lo Iudice G, Rispoli C, Verrillo A, D'Alessandro B.
    Minerva Endocrinol; 1994 Mar; 19(1):33-7. PubMed ID: 8035768
    [Abstract] [Full Text] [Related]

  • 10. Long-acting somatostatin analogues in pancreatic islet cell carcinoma.
    Souquet JC.
    Horm Res; 1989 Mar; 32(1-3):74-6. PubMed ID: 2559020
    [Abstract] [Full Text] [Related]

  • 11. No effect of the long-acting somatostatin analogue octreotide in patients with insulinoma.
    Timmer R, Koningsberger JC, Erkelens DW, Thijssen JH, Lips CJ, Koppeschaar HP.
    Neth J Med; 1991 Jun; 38(5-6):199-203. PubMed ID: 1922592
    [Abstract] [Full Text] [Related]

  • 12. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.
    Healy ML, Dawson SJ, Murray RM, Zalcberg J, Jefford M.
    Intern Med J; 2007 Jun; 37(6):406-9. PubMed ID: 17535385
    [Abstract] [Full Text] [Related]

  • 13. Effect of octreotide on plasma concentrations of glucose, insulin, glucagon, growth hormone, and cortisol in healthy dogs and dogs with insulinoma.
    Robben JH, van den Brom WE, Mol JA, van Haeften TW, Rijnberk A.
    Res Vet Sci; 2006 Feb; 80(1):25-32. PubMed ID: 15946716
    [Abstract] [Full Text] [Related]

  • 14. Successful long-term treatment with once-daily injection of low-dose octreotide in an aged patient with insulinoma.
    Katabami T, Kato H, Shirai N, Naito S, Saito N.
    Endocr J; 2005 Oct; 52(5):629-34. PubMed ID: 16284444
    [Abstract] [Full Text] [Related]

  • 15. Medical treatment of benign insulinoma using octreotide LAR: a case report.
    Usukura M, Yoneda T, Oda N, Yamamoto Y, Takata H, Hasatani K, Takeda Y.
    Endocr J; 2007 Feb; 54(1):95-101. PubMed ID: 17124362
    [Abstract] [Full Text] [Related]

  • 16. [Insulinoma and octreotide].
    Stehouwer C.
    Ned Tijdschr Geneeskd; 1992 Jun 20; 136(25):1221. PubMed ID: 1614574
    [No Abstract] [Full Text] [Related]

  • 17. Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations.
    Krentz AJ, Boyle PJ, Macdonald LM, Schade DS.
    Metabolism; 1994 Jan 20; 43(1):24-31. PubMed ID: 8289671
    [Abstract] [Full Text] [Related]

  • 18. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma.
    Verschoor L, Uitterlinden P, Lamberts SW, Del Pozo E.
    Clin Endocrinol (Oxf); 1986 Nov 20; 25(5):555-60. PubMed ID: 2887309
    [Abstract] [Full Text] [Related]

  • 19. The use of SMS 201-995 (somatostatin analogue) in insulinomas. Additional case report and literature review.
    Hearn PR, Ahmed M, Woodhouse NJ.
    Horm Res; 1988 Nov 20; 29(5-6):211-3. PubMed ID: 2851522
    [Abstract] [Full Text] [Related]

  • 20. Glucose-responsive and octreotide-sensitive insulinoma.
    Izumiyama H, Gotyo N, Fukai N, Ozawa N, Doi M, Yoshimoto T, Arii S, Hirata Y.
    Intern Med; 2006 Nov 20; 45(8):519-24. PubMed ID: 16702744
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.